

Pancreatic Cancer (Adenocarcinoma) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0 __IA __IB __IIA __IIB __III __IV __Recurrent

Line of Treatment: __ Neoadjuvant/Pre-Op __ Adjuvant/Post-Op __ First Line __ Second Line __ Third Line __ Third Line+

ECOG Performance Status: __ 0 __ 1 __ 2 __ 3 __ 4

Adjuvant Therapy

Capecitabine (Xeloda) and gemcitabine (Gemzar)

FULV: fluorouracil (5FU) and leucovorin

Gemcitabine (Gemzar)

Locally Advanced/Unresectable and Metastatic Disease | First Line of Therapy (1st Line) | ECOG PS: 0, 1, 2

FOLFIRINOX: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin

Gemcitabine (Gemzar)

Gemcitabine (Gemzar) and nab-paclitaxel (Abraxane)

Locally Advanced/Unresectable and Metastatic Disease | Second Line of Therapy (2nd Line) | ECOG PS: 0, 1, 2

OFF: Fluorouracil (5FU), leucovorin, and oxaliplatin

Gemcitabine (Gemzar)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

